|Bid||78.03 x 900|
|Ask||78.99 x 1800|
|Day's Range||77.96 - 81.40|
|52 Week Range||33.08 - 81.80|
|Beta (5Y Monthly)||1.17|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 09, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||90.70|
PITTSBURGH, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced that Krish S. Krishnan, Chairman and Chief Executive Officer will be participating in a fireside chat at the 41st Annual Cowen Health Care Conference taking place March 1-4, 2021. Details for the webcast are as follows: Presentation Date: Thursday, March 4, 2021 Presentation Time:9:50 AM – 10:20 AM EST Webcast link:https://wsw.com/webcast/cowen81/krys/1993389 A webcast of the presentation will be available for 90 days and can be found on the Krystal Biotech website at: http://ir.krystalbio.com/events-and-presentations/events. About Krystal BiotechKrystal Biotech, Inc. (NASDAQ:KRYS) is a pivotal-stage gene therapy company leveraging its novel, redosable gene therapy platform and in-house manufacturing capabilities to develop therapies to treat serious rare diseases. For more information, please visit http://www.krystalbio.com. Forward-Looking StatementsAny statements in this press release about future expectations, plans and prospects for Krystal Biotech, Inc., including but not limited to statements about the development of Krystal’s product candidates, such as plans for the design, conduct and timelines of ongoing clinical trials of beremagene geperpavec (“B-VEC”), KB105, KB104, KB301 and KB407; the clinical utility of B-VEC, KB105, KB104, KB301 and KB407, and Krystal’s plans for filing of regulatory approvals and efforts to bring B-VEC, KB105, KB104, KB301 and KB407 to market; the market opportunity for and the potential market acceptance of B-VEC, KB105, KB104, KB301 and KB407; plans to pursue research and development of other product candidates; the sufficiency of Krystal’s existing cash resources; the unanticipated impact of COVID-19 on Krystal’s business operations, pre-clinical activities and clinical trials; and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “likely,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties inherent in the initiation and conduct of clinical trials, availability and timing of data from clinical trials, whether results of early clinical trials or trials will be indicative of the results of ongoing or future trials, uncertainties associated with regulatory review of clinical trials and applications for marketing approvals, the availability or commercial potential of product candidates including B-VEC, KB105, KB104, KB301 and KB407, the sufficiency of cash resources and need for additional financing and such other important factors as are set forth under the caption “Risk Factors” in Krystal’s annual and quarterly reports on file with the U.S. Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent Krystal’s views as of the date of this release. Krystal anticipates that subsequent events and developments will cause its views to change. However, while Krystal may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Krystal’s views as of any date subsequent to the date of this release. CONTACTS: Investors:Whitney Ijemwijem@krystalbio.com Media:Mary CoyleTellMed Strategiesmary.firstname.lastname@example.org Source: Krystal Biotech, Inc.
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Krystal Biotech Inc (NASDAQ: KRYS) has priced the previously announced underwritten public offering of 1.923 million common shares at $65/share, representing gross proceeds of $125 million. Underwriters having an option to purchase up to an additional 288 thousand shares. Net proceeds from this offering together with its existing cash, cash equivalents, and short-term investments will be used to complete the ongoing pivotal trial of B-VEC for DEB and prepare for potential commercialization, advance the development of KB105 in TGM1-deficient ichthyosis, preclinical development of KB104 for Netherton syndrome, advance development of KB407 for cystic fibrosis, accelerate the Company's emerging respiratory pipeline, as well as for working capital and general corporate purposes. The offering is expected to close by February 5. KRYS shares are down 5.48% at $67.04 in the pre-market session on the last check Wednesday. See more from BenzingaClick here for options trades from BenzingaAmgen Shares Dip On Light 2021 Outlook, Paused StudiesEli Lilly, Innovent Biologics' Sintilimab Injection Receives China Approval For A Type Of Lung Cancer© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.